The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells

Metallomics

Volumn 7, Issue 1, 2015, Pages 165-173

  Zhang, Yan Fang ^a,b   Zhang, Min ^a,b   Huang, Xu Lei ^b   Fu, Yu Jie ^a,b   Jiang, Yu Han ^c   Bao, Ling Ling ^a,b   Maimaitiyiming, Yasen ^a,b   Zhang, Guang Ji ^d   Wang, Qian Qian ^a   Naranmandura, Hua ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL MEMBRANES; DISEASES; ELECTRIC RESISTANCE; METABOLITES; PATIENT TREATMENT; TUMORS;

DIMETHYLARSINOUS ACID; ENDOPLASMIC RETICULUM STRESS; INTERMEDIATE METABOLITES; MONOMETHYLARSONOUS ACIDS; POLY(ADP-RIBOSE) POLYMERASE; PROMYELOCYTIC LEUKEMIA; REACTIVE OXYGEN SPECIES; THERAPEUTIC STRATEGY;

ARSENIC;

ARSENITE SODIUM; CACODYLIC ACID; CRYPTOTANSHINONE; METHANEARSONIC ACID; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; APOPTOSIS REGULATORY PROTEIN; ARSENIC; PHENANTHRENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MTT ASSAY; BREAST TUMOR; DRUG EFFECTS; FEMALE; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; PHENANTHRENES; REACTIVE OXYGEN SPECIES;

EID: 84919924135     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c4mt00263f     Document Type: Article

References (29)

1. J. Zhu M. H. Koken F. Quignon M. K. Chelbi-Alix L. Degos Z. Y. Wang Z. Chen H. de Thé Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia Proc. Natl. Acad. Sci. U. S. A. 1997 94 3978 3983
2. P. Bobé D. Bonardelle K. Benihoud P. Opolon M. K. Chelbi-Alix Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice Blood 2006 108 3967 3975
3. R. W. Ahn F. Chen H. Chen S. T. Stern J. D. Clogston A. K. Patri M. R. Raja E. P. Swindell V. Parimi V. L. Cryns T. V. O'Halloran A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer Clin. Cancer Res. 2011 16 3607 3617
4. H. L. Kindler M. Aklilu S. Nattam E. E. Vokes Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium Am. J. Clin. Oncol. 2008 31 553 556
5. C. C. Lin C. Hsu C. H. Hsu W. L. Hsu A. L. Cheng C. H. Yang Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial Invest. New Drugs 2007 25 77 84
6. K. Rehman H. Naranmandura Double-edged effects of arsenic compounds: anticancer and carcinogenic effects Curr. Drug Metab. 2013 14 1029 1041
7. W. W. Wang Y. F. Lan K. Rehman Y. H. Jiang Y. Maimaitiyiming D. Y. Zhu H. Naranmandura Effect of Arsenic Compounds on the in Vitro Differentiation of Mouse Embryonic Stem Cells into Cardiomyocytes Chem. Res. Toxicol 2014 10.1021/tx500286t
8. D. J. Thomas The die is cast: arsenic exposure in early life and disease susceptibility Chem. Res. Toxicol. 2013 26 1778 1781
9. V. Charoensuk W. P. Gati M. Weinfeld X. C. Le Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells Toxicol. Appl. Pharmacol. 2009 239 64 70
10. K. Rehman Y. J. Fu Y. F. Zhang Q. Q. Wang B. Wu Y. Wu X. Y. Zhou W. H. Sun T. F. Sun H. Naranmandura Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species Metallomics 2014 6 1502 1512
11. J. Wu C. Henderson L. Feun P. Van Veldhuizen P. Gold H. Zheng T. Ryan L. S. Blaszkowsky H. Chen M. Costa B. Rosenzweig M. Nierodzik H. Hochster F. Muggia G. Abbadessa J. Lewis A. X. Zhu Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma Invest. New Drugs 2010 28 670 676
12. T. Hayashi T. Hideshima M. Akiyama P. Richardson R. L. Schlossman D. Chauhan N. C. Munshi S. Waxman K. C. Anderson Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment Mol. Cancer Ther. 2002 1 851 860
13. N. C. Munshi Arsenic trioxide: an emerging therapy for multiple myeloma Oncologist 2001 2 17 21
14. M. Baumgartner S. Sturlan E. Roth B. Wessner T. Bachleitner-Hofmann Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells Int. J. Cancer 2004 112 707 712
15. P. Liu S. Xu M. Zhang W. W. Wang Y. F. Zhang K. Rehman H. Naranmandura Z. Chen Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide Metallomics 2013 5 871 878
16. D. S. Shin H. M. Kim K. D. Shin Y. J. Yoon S. J. Kim D. C. Han B. M. Kwon Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells Cancer Res. 2009 69 193 202
17. 2+ stores Free Radical Biol. Med. 2004 37 1779 1789
18. W. Zhang H. T. Liu MAPK signal pathways in the regulation of cell proliferation in mammalian cells Cell Res. 2002 12 9 18
19. B. Bruno M. Rotta L. Giaccone M. Massaia A. Bertola A. Palumbo M. Boccadoro New drugs for treatment of multiple myeloma Lancet Oncol. 2004 5 430 442
20. J. Zhou Y. Zhang J. Li X. Li J. Hou Y. Zhao X. Liu X. Han L. Hu S. Wang Y. Zhao Y. Zhang S. Fan C. Lv L. Li L. Zhu Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia Blood 2010 115 1697 1702
21. K. B. Kim A. Y. Bedikian L. H. Camacho N. E. Papadopoulos C. McCullough A phase II trial of arsenic trioxide in patients with metastatic melanoma Cancer 2005 104 1687 1692
22. A. A. Tarhini J. M. Kirkwood H. Tawbi W. E. Gooding M. F. Islam S. S. Agarwala Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma Cancer 2008 112 1131 1138
23. B. Ardalan P. R. Subbarayan Y. Ramos M. Gonzalez A. Fernandez D. Mezentsev I. Reis R. Duncan L. Podolsky K. Lee M. Lima P. Ganjei-Azar A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma Clin. Cancer Res. 2010 16 3019 3027
24. L. Podolsky M. Oh P. R. Subbarayan D. Francheschi A. Livingstone B. Ardalan 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience Acta Oncol. 2011 50 602 605
25. J. C. Yang G. A. Cortopassi Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome c Free Radical Biol. Med. 1998 24 624 631
26. X. Jiang X. Wang Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1 J. Biol. Chem. 2000 275 31199 31203
27. M. Narita S. Shimizu T. Ito T. Chittenden R. J. Lutz H. Matsuda Y. Tsujimoto Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria Proc. Natl. Acad. Sci. U. S. A. 1998 95 14681 14686
28. M. Woo R. Hakem M. S. Soengas G. S. Duncan A. Shahinian D. H. Kagi A. Hakem M. McCurrach W. Khoo S. A. Kaufman G. Senaldi T. Howard S. W. Lowe T. W. Mak Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes Genes Dev. 1998 12 806 819
29. H. Naranmandura X. Chen M. Tanaka W. Wang K. Rehman S. Xu Z. Chen S. Q. Chen N. Suzuki Release of apoptotic cytochrome c from mitochondria by dimethylarsinous acid occurs through interaction with voltage-dependent anion channel in vitro Toxicol. Sci. 2012 128 137 146